Open AccessInitiation Patterns of Statins in the 2 Years After Release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) Cholesterol Management Guideline in a Large US Health Plan
Author(s) -
Olufade Temitope,
Zhou Siting,
Anzalone Deborah,
Kern David M.,
Tunceli Ozgur,
Cziraky Mark J.,
Willey Vincent J.
Publication year - 2017
Publication title -
journal of the american heart association
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.494
H-Index - 85
ISSN - 2047-9980
DOI - 10.1161/jaha.116.005205
Subject(s) - medicine , statin , guideline , diabetes mellitus , observational study , population , cholesterol , specialty , cardiology , atorvastatin , retrospective cohort study , endocrinology , family medicine , environmental health , pathology
Background The purpose of this study was to characterize changes in statin utilization patterns in patients newly initiated on therapy in the 2 years following the release of the 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol management guideline in a large US health plan population. Methods and Results This retrospective, observational study used administrative medical and pharmacy claims data to identify patients newly initiated on statin therapy over 4 quarters prior to and 8 quarters following the release of the guideline (average N/quarter=3596). Patients were divided into the 4 statin benefit groups ( SBG s) based on risk factors and laboratory lipid levels as defined in the guideline: SBG 1 (with atherosclerotic cardiovascular disease [ ASCVD ]; N=1046/quarter), SBG 2 (without ASCVD , with low‐density lipoprotein cholesterol ≥190 mg/dL; N=454/quarter), SBG 3 (without ASCVD , aged 40–75 years, with diabetes mellitus, low‐density lipoprotein cholesterol 70–189 mg/dL; N=1391/quarter), SBG 4 (no ASCVD or diabetes mellitus, age 40–75 years, low‐density lipoprotein cholesterol 70–189 mg/dL, estimated 10‐year ASCVD risk of ≥7.5%; N=705/quarter). Demographic variables, statin utilization patterns, lipid levels, and comorbidities were analyzed for pre‐ and postguideline periods. Postguideline, gradually increased high‐intensity statin initiation occurred in SBG 1, SBG 2, and in SBG 3 patients with 10‐year ASCVD risk ≥7.5%. Moderate‐ to high‐intensity statin initiation gradually increased among SBG 4 patients. Recommended‐intensity statin choice changed to a greater degree among patients treated by specialty care physicians. Regarding sex, target‐intensity statin initiation was lower in women in all groups before and after guideline release. Conclusions Prescriber implementation of the guideline recommendations has gradually increased, with the most marked change in the increased initiation of high‐intensity statins in patients with ASCVD and in those treated by a specialist.